Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor - Trial NCT06218069
Access comprehensive clinical trial information for NCT06218069 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Radboud University Medical Center and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Radboud University Medical Center
Timeline & Enrollment
Phase 2/3
Mar 01, 2024
Mar 01, 2027
Primary Outcome
Number of participants with successful completion of curative surgery within 42 days after start of subcutaneous sasanlimab as neo-adjuvant treatment.,The number of CTC grade ≥3 toxicity related to subcutaneous sasanlimab as neo-adjuvant treatment.,Detection of treatment induced immune related responses after subcutaneous sasanlimab as neo-adjuvant treatment.
Summary
This study investigates whether a single subcutaneous administration of anti-PD-1 antibody
 can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with
 [89Zr]crefmirlimab berdoxam PET imaging as an imaging biomarker.
Data Source
ClinicalTrials.gov
NCT06218069
Non-Device Trial